Overview of the most common skin adverse reactions of biological treatment in patients with inflammatory bowel disease, including an algorithm for their differential diagnosis – part 2
Michaela Nováková1,2
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Antonelli E, Bassotti G, Tramontana M et al. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med 2021; 10(2): 364. doi: 10.3390/jcm10020364.
2. Pagani K, Lukac D, Bhukhan A et al. Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview. Am J Clin Dermatol 2022; 23(4): 481–497. doi: 10.1007/s40257-022-00689-w.
3. Lambert JLW, De Schepper S, Speeckaert R. Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. J Clin Med 2021; 10(5): 1040. doi: 10.3390/jcm10051040.
4. Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. Treasure Island (FL): StatPearls Publishing 2022.
5. Alvarez-Payares JC, Ramírez-Urrea S, Correa-Parra L et al. Mucocutaneous Manifestations of Inflammatory Bowel Disease. Cureus 2021; 13 (8): e17191. doi: 10.7759/cureus.17191.
6. Bucalo A, Rega F, Zangrilli A et al. Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers. Int J Mol Sci 2020; 21(21): 7873. doi: 10.3390/ijms21217873.
7. Jeong KM, Seo JY, Kim A et al. Tumor Necrosis Factor-Alpha Inhibitor-Associated Psoriatic Alopecia in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature. Ann Dermatol 2021; 33(1): 82–85. doi: 10.5021/ad.2021.33.1.82.
8. Alinaghi F, Tekin HG, Burisch J et al. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis 2020; 14(3): 351–360. doi: 10.1093/ecco-jcc/jjz152.
9. Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol 2018; 9: 2746. doi: 10.3389/fimmu.2018.02746.
10. Townsend CM, Lovegrove F, Khanna R et al. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022; 55(11): 1379–1388. doi: 10.1111/apt.16883.
11. Hedin CRH, Sonkoly E, Eberhardson M et al. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med 2021; 290(2): 257–278. doi: 10.1111/joim.13282.